What endurance athletes know about brain health that most neurologists don't

The brain is a paradox. It constitutes roughly 2% of body weight but consumes approximately 20% of total energy - almost entirely as glucose under normal conditions. Unlike muscle or liver, neurons cannot store meaningful fuel reserves. They live or die by the constancy of their energy supply. Any disruption - even brief - causes immediate dysfunction. In neurodegenerative diseases such as Alzheimer's and Parkinson's, mitochondrial failure precedes and likely drives neuronal death by years, sometimes decades.

While direct clinical data on SLU-PP-332 in human brain tissue remain limited, the mechanistic framework - combined with emerging preclinical evidence - provides a scientifically grounded basis for exploring its neurological potential.

ERR Expression in the Brain

ERRα and ERRγ are expressed in specific brain regions, including the cerebral cortex, hippocampus, and cerebellum - areas critical for cognition, memory, and motor coordination. ERRγ in particular shows high constitutive activity in neurons and is considered a key regulator of neuronal mitochondrial biogenesis and synaptic energy supply. These receptors do not merely exist in the brain - they perform essential functions that parallel their roles in peripheral tissues.

Brain-Specific Metabolic Considerations

The brain's relationship with SLU-PP-332 is nuanced and distinct from that of muscle, liver, or kidney:

Glucose dependence remains paramount

Unlike peripheral tissues, neurons cannot simply switch from glucose to fat oxidation. The shift that SLU-PP-332 drives in skeletal muscle - toward beta-oxidation - is tightly restricted in neurons. However, CPT1C, a brain-specific isoform of CPT1, modulates energy sensing and ceramide metabolism without driving classical fatty acid oxidation, suggesting a distinct but relevant metabolic role.

UCP2 and ROS management

Uncoupling Protein 2 (UCP2) is upregulated in neurons downstream of PGC-1α activation. In the brain, UCP2 serves primarily as a reactive oxygen species (ROS) buffer rather than a thermogenic switch. By mildly uncoupling the mitochondrial membrane potential, UCP2 reduces electron leakage and oxidative damage - a critical function in long-lived post-mitotic neurons that cannot be replaced if lost.

Neuroinflammation and microglial metabolism

Neuroinflammatory states, characteristic of Alzheimer's, Parkinson's, and traumatic brain injury, involve microglial activation with altered metabolic phenotypes. ERR agonism may modulate microglial metabolism in ways that reduce neuroinflammatory burden - though this remains an active area of investigation.

Potential for Cognitive Protection

The mechanistic case for SLU-PP-332 in neurological protection rests on three pillars: first, restoration of mitochondrial biogenesis in energy-demanding neurons; second, upregulation of UCP2-mediated ROS management, reducing oxidative damage; and third, PGC-1α-driven enhancement of synaptic mitochondrial density, which supports the energy-intensive processes of synaptic transmission and long-term potentiation - the cellular basis of memory formation.

These mechanisms collectively suggest that SLU-PP-332 may support neuronal resilience, helping brain cells survive metabolic stress rather than restoring function once lost. Prevention, in this context, is not merely preferable; it may be the only realistic therapeutic window.

What We Do Not Yet Know

Whether SLU-PP-332 crosses the blood-brain barrier at therapeutically relevant concentrations in vivo remains to be established. Its next-generation analogue SLU-PP-915 has demonstrated improved oral bioavailability, and ongoing pharmacokinetic optimisation may yield compounds with CNS penetrance. Until then, the neurological effects of this compound class warrant rigorous investigation - given both the mechanistic plausibility and the catastrophic unmet need in neurodegenerative disease.

Warning:
SLU-PP-332 is a research compound not approved for human use. This content is produced exclusively for educational and informational purposes. Nothing contained herein constitutes or should be interpreted as medical advice, a clinical recommendation, a diagnostic opinion, or an endorsement of any specific treatment, supplement, or intervention. Always consult a qualified and licensed medical professional before making decisions regarding your health, supplementation, or medical care. The author and publisher of this content accept no liability for any actions taken or not taken based on the information provided herein.

Bibliography & Sources

Billon C, Sitaula S, Banerjee S, et al. Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity. ACS Chemical Biology. 2023;18(4):756–771. doi:10.1021/acschembio.2c00720. PMID: 36988910. 

de Souza-Lima J, Astrosa-Martin BD, et al. Pharmacological Activation of ERRα/β/γ as an Exercise Mimetic: Potential Therapeutic Applications. Revista Médica de Chile. 2026;154(2):237–245. doi:10.4067/s0034-98872026000200237. PMID: 42024694. 

Okda HE, Zhao P, Hayes M, et al. Chemical Optimization of the Exercise Mimetic SLU-PP-332 Enables Insight into Estrogen-Related Receptor Signaling. International Journal of Biological Macromolecules. 2026;355:151450. doi:10.1016/j.ijbiomac.2026.151450. PMID: 41850449. 

Billon C, Appourchaux K, Côté I, Burris TP. An Orally Active Estrogen Receptor-Related Receptor Agonist, SLU-PP-915, Enhances Aerobic Exercise Capacity. Journal of Pharmacological and Experimental Therapeutics. 2026;393(1):103787. doi:10.1016/j.jpet.2025.103787. PMID: 41421047. 

Wang XX, Myakala K, Libby AE, et al. Estrogen-Related Receptor Agonism Reverses Mitochondrial Dysfunction and Inflammation in the Aging Kidney. American Journal of Pathology. 2023;193(12):1969–1987. doi:10.1016/j.ajpath.2023.07.008. PMID: 37717940.

This article is for informational purposes only and is not intended as medical advice. It should not replace professional medical assessment, diagnosis, or treatment. If you have health concerns, please consult a qualified healthcare professional.